Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study.
It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose (IV FCM), which is the standard second-line treatment for iron deficiency anaemia (IDA).
Ulker says the data from the multi-national phase 3b randomised trial in inflammatory bowel disease (IBD) patients with IDA, supports the headline data reported back in March and provides additional material to support commercialisation and reimbursement efforts.
